Saint Luke's cardiologists performed the world's first balloon angioplasty in an acute heart attack patient in 1981. Since then, we've developed many new treatments for improving coronary and vascular circulation and have pioneered catheter-based treatments for structural heart disease. For example,
- Saint Luke’s offers the region’s only treatment option for cardiac patients considered too high-risk or inoperable for conventional aortic valve replacement surgery.
- We’ve developed many new treatments for improving coronary and vascular circulation and have pioneered catheter-based treatments for structural heart disease. For example, Saint Luke’s uses an innovative new approach to angioplasty, known as FFR-guided percutaneous coronary intervention, in many of our patients, which reduces their need for stents and improves their outcomes.
- Saint Luke’s is a world leader in treating chronic total occlusions (CTOs), or arteries that are completely blocked by plaque buildup. Traditionally, CTOs have been treated with medication or bypass surgery. But Saint Luke’s physicians have perfected a new minimally invasive technique for opening CTOs in 90 percent of cases, resulting in reduced complications and faster recovery times for patients. Today, these pioneering physicians travel the world teaching other cardiologists this technique.
- Saint Luke's was a lead enroller in the Protect AF trial, which helps patients at risk for embolism but who aren't candidates for anticoagulants.
- Saint Luke's participated in the first international collaborative study using stem cells in interventional cardiology. Preliminary results show that autologous stem cells can be successfully used to treat patients with severe coronary artery disease who aren't candidates for surgery or angioplasty.
4401 Wornall Rd
Kansas City, MO 64111
5844 NW Barry Rd, Ste 230
Kansas City, MO 64154
12300 Metcalf Ave, Ste 280
Overland Park, KS 66213
20 NE Saint Luke's Blvd, Ste 240
Lee's Summit, MO 64086